TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3545642

Group type: EXPERIMENTAL
Intervention: Lipid infusion into the duodenum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid infusion into the ileum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of corn oil to a meal of mashed potato
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fat-containing meal
Number of subjects: 0
Study: 29222541

Group type: EXPERIMENTAL
Intervention: Multimodal screening (MMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study: 27000249

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a (SC IFNB‐1a) 44 μg three times weekly
Number of subjects: 0
Study: 25783198

Group type: EXPERIMENTAL
Intervention: Low-dose multislice computed tomography (MSCT) screening
Number of subjects: 0
Study: 23985210

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (routine therapy)
Number of subjects: 60
Study: 21875633

Group type: EXPERIMENTAL
Intervention: mpHBV-Hib
Number of subjects: 543

Group type: COMPARATOR
Intervention: Comvax™ (control)
Number of subjects: 543
Study: 19289636

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (n=52)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Resistance training (n=54)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Resistance plus aerobic training (n=53)
Number of subjects: 209

Group type: COMPARATOR
Intervention: No training (control group, n=50)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Detraining (after 1 month)
Number of subjects: 209
Study: 17190530

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 0
Study: 15526804

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone combination 50/500mcg bid
Number of subjects: 719

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 719
Study: 11212999

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg every 6 h)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Oral misoprostol (50 microg every 6 h)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 167

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 167
Study: 9043898

Group type: EXPERIMENTAL
Intervention: Humegon (FSH/LH ratio 1:1) via subcutaneous (s.c.) administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Humegon (FSH/LH ratio 1:1) via intramuscular (i.m.) administration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Normegon (FSH/LH ratio 3:1) via subcutaneous (s.c.) administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normegon (FSH/LH ratio 3:1) via intramuscular (i.m.) administration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both preparations (Humegon and Normegon)
Number of subjects: 18
Study: 7779855

Group type: EXPERIMENTAL
Intervention: BT563 (murine anti-interleukin-2 receptor monoclonal antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Murine monoclonal CD3 antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BT563 treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy specimens from rejecting grafts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy specimens from patients without rejection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biopsy material from rejecting grafts
Number of subjects: 0
Study: 2245613

Group type: EXPERIMENTAL
Intervention: Closed suction (Trach Care Closed Suction System)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Open suction method
Number of subjects: 84
Study: 668932

Group type: EXPERIMENTAL
Intervention: 15.9-mm vacuum system
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-mm vacuum system
Number of subjects: 0
Study: 31422134

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 31322086

Group type: EXPERIMENTAL
Intervention: Meldonium plus standard antianginal and antiarrhythmic therapy for 2 months
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard antianginal and antiarrhythmic therapy only
Number of subjects: 147
Study: 28141942

Group type: EXPERIMENTAL
Intervention: Reverse breech extraction approach
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 192
Study: 25455433

Group type: EXPERIMENTAL
Intervention: Hard metatarsal pads (n=6, thermoplastic, ShoreA65)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soft metatarsal pads (n=6, latex foam, Shore A11)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control test (auditory sensations)
Number of subjects: 12
Study: 26591621

Group type: EXPERIMENTAL
Intervention: Fluoride-free, alcohol-free mouthwash containing 0.075% CPC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluoride-free, alcohol-free mouthwash containing 0.07% CPC
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-antibacterial mouthwash
Number of subjects: 120
Study: 23122974

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg loading dose followed by 30 μg/kg/min infusion)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 56
Study: 21073744

Group type: EXPERIMENTAL
Intervention: Small group tutorials
Number of subjects: 107

Group type: COMPARATOR
Intervention: Interactive seminars
Number of subjects: 107
Study: 18186737

Group type: EXPERIMENTAL
Intervention: Dual-cured luting cement (RelyX ARC; 3M ESPE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Light-cured luting cement (RelyX Veneer; 3M ESPE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both cement types
Number of subjects: 40
Study: 17023237

Group type: COMPARATOR
Intervention: Electromechanical gait trainer (EGT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electromechanical gait trainer with functional electric stimulation (EGT‐FES)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional gait training (CGT)
Number of subjects: 50
Study: 12741866

Group type: EXPERIMENTAL
Intervention: Magnetic shoe insoles (600 gauss)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Magnetic shoe insoles (125 gauss)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40‐yd dash performance
Number of subjects: 14
Study: 11062355

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8990429

Group type: EXPERIMENTAL
Intervention: One-layer closure
Number of subjects: 164

Group type: COMPARATOR
Intervention: Two-layer closure
Number of subjects: 164
Study: 7638522

Group type: EXPERIMENTAL
Intervention: Guaraná
Number of subjects: 30

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3128318

Group type: EXPERIMENTAL
Intervention: Alfentanil 400 micrograms
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Alfentanil 600 micrograms
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Alfentanil 800 micrograms
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Alfentanil 1000 micrograms
Number of subjects: 55
Study: 31402637

Group type: EXPERIMENTAL
Intervention: Rocuronium (group R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vecuronium (group V)
Number of subjects: 60
Study: 30260460

Group type: EXPERIMENTAL
Intervention: L-arginine 6 g/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27392904

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin for 6 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 64
Study: 25917265

Group type: EXPERIMENTAL
Intervention: Balneotherapy with mud-pack and hot pool treatments
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (patient education alone)
Number of subjects: 70
Study: 23837171

Group type: EXPERIMENTAL
Intervention: Metal-Ceramic crowns (MC) with glass-fiber posts (GFPs) and composite cores
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All-Ceramic crowns (AC) with glass-fiber posts (GFPs) and composite cores
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (intact canines)
Number of subjects: 50
Study: 21115454

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 h for 5-14 days
Number of subjects: 702

Group type: COMPARATOR
Intervention: Vancomycin 1 g plus aztreonam 1 g every 12 h for 5-14 days
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 702

Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam
Number of subjects: 702
Study: 18222256

Group type: EXPERIMENTAL
Intervention: Saphenous vein graft markers
Number of subjects: 1778
Study: 16758259

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily for 18 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline S‐warfarin AUC(0‐infinity)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Inhibition period S‐warfarin AUC(0‐infinity)
Number of subjects: 18
Study: 14610396

Group type: EXPERIMENTAL
Intervention: PCE in alveolar air (PCE‐Alv)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PCE in blood (PCE‐B)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PCE in urine (PCE‐U)
Number of subjects: 26
Study: 11080324

Group type: EXPERIMENTAL
Intervention: Nurse‐managed intervention for smoking cessation and relapse prevention during hospitalization
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 278
Study: 8966087

Group type: EXPERIMENTAL
Intervention: Fish oil (15 ml daily for 12 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sunflower oil (control group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 37
Study: 7880657

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (CSA) using a 32‐gauge polyimide microcatheter
Number of subjects: 128

Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia (SDSA) with a 24‐gauge x 103‐mm Sprotte spinal needle
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (CSA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia (SDSA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Continuous spinal anaesthesia (CSA) and Single-dose spinal anaesthesia (SDSA)
Number of subjects: 128
Study: 2906764

Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (OC)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Progestogen-only pill
Number of subjects: 341

Group type: COMPARATOR
Intervention: Nonhormonal methods
Number of subjects: 341
Study: 28703949

Group type: EXPERIMENTAL
Intervention: IPSRT + quetiapine
Number of subjects: 92

Group type: COMPARATOR
Intervention: IPSRT + placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Preferred treatment assignment
Number of subjects: 92
Study: 26714490

Group type: EXPERIMENTAL
Intervention: Bowel-cleansing preparations satisfaction measure (Domain 1)
Number of subjects: 1211
Study: 26719313

Group type: EXPERIMENTAL
Intervention: High-income source abstracts
Number of subjects: 899

Group type: COMPARATOR
Intervention: Low-income source abstracts
Number of subjects: 899
Study: 22985998

Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behaviour therapy (CBT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Psycho-education
Number of subjects: 44
Study: 22053621

Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients without glucose (HD-g(-))
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Conservatively treated CRF patients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients with glucose (HD-g(+))
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 87
Study: 19463293

Group type: EXPERIMENTAL
Intervention: Direct stenting with TAXUS Liberté
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-dilation
Number of subjects: 0
Study: 17111989

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard psychiatric treatments (treatment as usual)
Number of subjects: 6
Study: 12583870

Group type: EXPERIMENTAL
Intervention: Granisetron (GRA) 1 mg/ml injected into the masseter muscle
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isotonic saline injected into the masseter muscle
Number of subjects: 18
Study: 10898121

Group type: EXPERIMENTAL
Intervention: Amtolmetin guacyl (600 mg on an empty stomach, once daily for 30 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Piroxicam (20 mg on a full stomach, once daily for 30 days)
Number of subjects: 99
Study: 9238884

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% PVM/MA copolymer in a 0.331% NaF/silica (1500 ppm F) base
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Dentifrice containing 0.331% NaF/silica (1500 ppm F) without triclosan and copolymer
Number of subjects: 1296
Study: 1622733

Group type: EXPERIMENTAL
Intervention: PSK (3.0 g orally before surgery, daily or every other day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no PSK)
Number of subjects: 47
Study: 6694339

Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 300
Study: 31347295

Group type: EXPERIMENTAL
Intervention: Prone stereotactic guidance
Number of subjects: 116

Group type: COMPARATOR
Intervention: Upright tomosynthesis guidance
Number of subjects: 116
Study: 29054532

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 26872703

Group type: EXPERIMENTAL
Intervention: Web-based coaching program (fully automated) including education, motivation, exercise guidance, daily text message reminders, and weekly feedback.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care and advice from practitioner (control group).
Number of subjects: 93

Group type: COMPARATOR
Intervention: Comparison between intervention and control groups.
Number of subjects: 93
Study: 24155058

Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg once daily for 14 days plus etravirine 800 mg twice daily for 21 days (days 8-21)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily for 13 days plus etravirine 200 mg twice daily for 8 days (days 6-13)
Number of subjects: 32
Study: 22015542

Group type: EXPERIMENTAL
Intervention: SMART treatment (budesonide/formoterol 80/4.5 μg Turbuhaler®, two puffs once daily and extra inhalations as needed)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SMART treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: UC treatment
Number of subjects: 102
Study: 20439575

Group type: EXPERIMENTAL
Intervention: Growth hormone (2 mg/d subcutaneously)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Growth hormone (2 mg/d)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Growth hormone (2 mg/d) with testosterone (250 mg/wk intramuscularly)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 17427828

Group type: EXPERIMENTAL
Intervention: Xeno III one‐step self‐etch adhesive (Dentsply/Caulk)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT total‐etch adhesive (Dentsply/Caulk)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: i‐Bond one‐step self‐etch adhesive (Heraeus Kulzer)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond two‐step self‐etch adhesive (Kuraray Medical)
Number of subjects: 30
Study: 15730611

Group type: EXPERIMENTAL
Intervention: Apex auscultation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Carotid pulse palpation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Brachial pulse palpation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Femoral pulse palpation
Number of subjects: 56
Study: 11929643

Group type: EXPERIMENTAL
Intervention: 20 EE
Number of subjects: 48

Group type: COMPARATOR
Intervention: 30 EE
Number of subjects: 48
Study: 9928553

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endocrine manipulation (future trials)
Number of subjects: 0
Study: 7637824

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen breathing for 15‐20 min before radiotherapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 47
Study: 2692891

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 150
Study: 625655

Group type: EXPERIMENTAL
Intervention: Diclofenac (Voltaren) 75 mg daily from week 4
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen (Proxen) 500 mg daily from week 4
Number of subjects: 40
Study: 30442052

Group type: EXPERIMENTAL
Intervention: Telemonitoring dietary advice (Tele‐GDM group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (traditional follow-up)
Number of subjects: 57
Study: 28259854

Group type: EXPERIMENTAL
Intervention: Early physiotherapy intervention starting at 2 weeks after randomisation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care physiotherapy starting at 6 weeks after randomisation
Number of subjects: 80
Study: 25760742

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 0
Study: 24055681

Group type: EXPERIMENTAL
Intervention: VEN‐CBT
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: VEN‐Progressive Muscle Relaxation therapy (PMR)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Placebo (PLC)‐CBT
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (PLC)‐PMR
Number of subjects: 81
Study: 20739054

Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg once daily)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 19169289

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 18 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 12 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Daily filgrastim (10 microg/kg for < or =7 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Daily filgrastim (5 microg/kg/day for < or =14 days)
Number of subjects: 61
Study: 17482099

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylaxis strategies for CIN
Number of subjects: 0
Study: 15480402

Group type: EXPERIMENTAL
Intervention: Pamidronate infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (traditional immobilization methods)
Number of subjects: 23
Study: 11296091

Group type: EXPERIMENTAL
Intervention: SR141716 (90 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SR141716 (1, 3, 10, 30, and 90 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 9416985

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 9903

Group type: EXPERIMENTAL
Intervention: Isradipine sustained release
Number of subjects: 9903

Group type: COMPARATOR
Intervention: Other active drugs
Number of subjects: 9903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9903
Study: 8293730

Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Prior occurrence of posttreatment nervousness
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Anxiety before the 1st infusion
Number of subjects: 53
Study: 3323290

Group type: EXPERIMENTAL
Intervention: iv calcium infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: oral diltiazem administration for one week
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: acute iv diltiazem infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GnRH-TRH stimulation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: calcium and diltiazem treatments
Number of subjects: 6
Study: 31501078

Group type: EXPERIMENTAL
Intervention: Balloon inflation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ball squeezing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Coughing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 28422576

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (BCBT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 152
Study: 27138028

Group type: EXPERIMENTAL
Intervention: Opicapone (5, 25, or 50mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 24144628

Group type: EXPERIMENTAL
Intervention: Potato-derived balanced 6% HES 130/0.42 with 500 mL of Ringer's lactate (HESPRL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Potato-derived balanced 6% HES 130/0.42 (HESP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Waxy maize-derived balanced 6% HES 130/0.4 with 500 mL of Ringer's lactate (HESMRL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Waxy maize-derived balanced 6% HES 130/0.4 (HESM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 22234633

Group type: EXPERIMENTAL
Intervention: XELOX plus bevacizumab
Number of subjects: 480

Group type: COMPARATOR
Intervention: bevacizumab
Number of subjects: 480
Study: 20484550

Group type: EXPERIMENTAL
Intervention: Isoflavones (daidzein)
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: Isoflavones (genistein)
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: RBC (n-3) fatty acids (eicosapentaenoic acid - EPA)
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: RBC (n-3) fatty acids (docosapentaenoic acid - DPA)
Number of subjects: 1293
Study: 18755353

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16798053

Group type: EXPERIMENTAL
Intervention: GAITRite gait analysis system
Number of subjects: 13